{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:01:13Z","timestamp":1768510873159,"version":"3.49.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Telitacicept and belimumab are the only two approved biologics in China for treating systemic lupus erythematosus (SLE). With the widespread clinical use of biologics, more reliable clinical evidence has been provided. This study seeks to evaluate the cost-effectiveness of two biologic treatments for SLE in China by utilizing current medication prices and the most recent clinical research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cost-effectiveness analysis comparing telitacicept and belimumab was conducted by developing a lifetime SLE partition survival model using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2\u202fK) score, which considers the relationship between organ damage and death. The data were extracted from the literature with model assumptions. Scenario analysis of short term treatment (5\u202fyears) and typical one-way and probabilistic sensitivity analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After lifetime simulation, compared to belimumab treatment, telitacicept treatment can save a total of \u00a557751.00, including expenses of drug usage and treatment of complications. Meanwhile, it gained 0.499 quality adjusted life years, resulted in a negative ICER. Telitacicept is more cost-saving than belimumab (Dominant).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Under current pricing, treatment settings and efficacy data in China, telitacicept demonstrates superior cost-effectiveness compared with belimumab for long-term SLE management by reducing medication costs while delivering additional health benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2025.1712454","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:24:21Z","timestamp":1768458261000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-utility analysis of telitacicept versus belimumab in the treatment of systemic lupus erythematosus in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Chang","family":"Liu","sequence":"first","affiliation":[{"name":"Center for Health Policy and Technology Evaluation, Peking University Health Science Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libo","family":"Tao","sequence":"additional","affiliation":[{"name":"Center for Health Policy and Technology Evaluation, Peking University Health Science Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Yan","sequence":"additional","affiliation":[{"name":"Center for Health Policy and Technology Evaluation, Peking University Health Science Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Wu","sequence":"additional","affiliation":[{"name":"Center for Health Policy and Technology Evaluation, Peking University Health Science Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangxu","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Health Policy and Technology Evaluation, Peking University Health Science Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Sun","sequence":"additional","affiliation":[{"name":"Center for Health Policy and Technology Evaluation, Peking University Health Science Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(14)60128-8","article-title":"Systemic lupus erythematosus","volume":"384","author":"Lisnevskaia","year":"2014","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.16150\/j.1671-2870.2024.03.002","article-title":"Current status and challenges in the diagnosis and treatment of systemic lupus erythematosus in China","volume":"23","author":"Zhang","year":"2024","journal-title":"J Diag Conc Pract"},{"key":"ref5","volume-title":"Study on quality of life and its influencing factors in patients with systemic lupus erythematosus","author":"Yang","year":"2021"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3760\/cma.j.cn112137-20250228-00479","article-title":"Chinese guidelines for the diagnosis and management of systemic lupus erythematosus (2025 edition)","volume":"105","year":"2025","journal-title":"Chin Med J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0961203319828519","article-title":"The impact of SLE on health-related quality of life assessed with SF-36: a systemic review and meta-analysis","volume":"28","author":"Gu","year":"2019","journal-title":"Lupus"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrrheum.2016.137","article-title":"The global burden of SLE: prevalence, health disparities and socioeconomic impact","volume":"12","author":"Carter","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/0961203321990086","article-title":"Hospitalization in patients with systemic lupus erythematosus at Tawam hospital, United Arab Emirates (UAE): rates, causes, and factors associated with length of stay","volume":"30","author":"Aldarmaki","year":"2021","journal-title":"Lupus"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10067-024-07266-y","article-title":"Effectiveness and safety of belimumab and telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study","volume":"44","author":"Jin","year":"2025","journal-title":"Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1423035","DOI":"10.3389\/fimmu.2024.1423035","article-title":"Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: a real-life, single-center observational study","volume":"15","author":"Fan","year":"2024","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10238-025-01640-z","article-title":"Evaluation of the efficacy and safety of belimumab and Telitacicept in patients with systemic lupus erythematosus: results from a retrospective, observational study","volume":"25","author":"Feng","year":"2025","journal-title":"Clin Exp Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/annrheumdis-2024-eular.3775","article-title":"POS0535 comparison of TELITACICEPT and BELIMUMAB in patients with SLE","volume":"83","author":"Liu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e001296","DOI":"10.1136\/lupus-2024-001296","article-title":"Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study","volume":"12","author":"Chen","year":"2025","journal-title":"Lupus Sci Med"},{"key":"ref16","first-page":"2202","article-title":"Construction of health economics evaluation model for systemic lupus erythematosus","volume":"60","author":"Liu","year":"2025","journal-title":"Chin Pharm J"},{"key":"ref17","volume-title":"Statistical bulletin on the development of China\u2019s health and wellness industry 2024","year":"2025"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e000446","DOI":"10.1136\/lupus-2020-000446","article-title":"Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical Centre","volume":"8","author":"Hill","year":"2021","journal-title":"Lupus Sci Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/rheumatology\/keae120","article-title":"Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up","volume":"64","author":"Parodis","year":"2025","journal-title":"Rheumatology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s12325-022-02332-w","article-title":"Cost-effectiveness of Acthar gel versus standard of Care for the Treatment of exacerbations in moderate-to-severe systemic lupus erythematosus","volume":"40","author":"Bindra","year":"2023","journal-title":"Adv Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.3390\/ijerph20043522","article-title":"Annual direct cost and cost-drivers of systemic lupus erythematosus: a multi-center cross-sectional study from CSTAR registry","volume":"20","author":"Wang","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"A113","DOI":"10.1136\/lupus-2023-lupus21century.98","article-title":"1501 long-term safety of belimumab among adult patients with systemic lupus erythematosus (SLE): pooled data from three open-label extension studies over 11+ years","volume":"11","author":"Mian","year":"2024","journal-title":"Lupus Sci Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1093\/rheumatology\/keab080","article-title":"EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus","volume":"60","author":"Lindblom","year":"2021","journal-title":"Rheumatology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1093\/rheumatology\/keac185","article-title":"Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus","volume":"61","author":"Emamikia","year":"2022","journal-title":"Rheumatology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1092325","DOI":"10.3389\/fmed.2022.1092325","article-title":"EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus","volume":"9","author":"Lindblom","year":"2022","journal-title":"Front Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1093\/rheumatology\/kead140","article-title":"Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing adequate health state","volume":"62","author":"Hua","year":"2023","journal-title":"Rheumatology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40273-020-00984-6","article-title":"Health state utilities of patients with heart failure: a systematic literature review","volume":"39","author":"Di Tanna","year":"2021","journal-title":"PharmacoEconomics"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.36469\/9685","article-title":"Disutility study for adult patients with moderate to severe Crohn\u2019 s disease","volume":"6","author":"Worbes-Cerezo","year":"2019","journal-title":"J Health Econ Outcomes Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12955-018-0979-7","article-title":"Health-related quality of life in relation to symptomatic and radiographic definitions of knee osteoarthritis: data from osteoarthritis initiative (OAI) 4-year followup study","volume":"16","author":"Tormalehto","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12955-015-0262-0","article-title":"Elicitation of health state utilities associated with varying severities of flares in systemic lupus erythematosus","volume":"13","author":"Pollard","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/archophthalmol.2008.608","article-title":"Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome","volume":"127","author":"Brown","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3109\/15412555.2015.1092953","article-title":"Health state utility value in chronic obstructive pulmonary disease (COPD); the challenge of heterogeneity: a systematic review and meta-analysis","volume":"13","author":"Moayeri","year":"2016","journal-title":"COPD: J Chron Obstruct Pulmon Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12955-020-01559-x","article-title":"Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review","volume":"18","author":"Cooper","year":"2020","journal-title":"Health Qual Life Outcomes"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1712454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:24:24Z","timestamp":1768458264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1712454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":34,"alternative-id":["10.3389\/fpubh.2025.1712454"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1712454","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"1712454"}}